The effects of Rimazolam on oxidative stress level, sedation score, and recovery time of patients under different doses in hip replacement are investigated. A total of 100 patients who underwent hip arthroplasty in our hospital from September 2020 to May 2022 are selected as the study subjects. According to the random number table method, they are divided into observation group and control group. The observation group is given 0.3 mg/kg Rimazolam, and the control group is given 0.4 mg/kg Rimazolam. Oxidative stress level, hemodynamic indexes at different time after anesthesia, sedation score and sedation depth, Visual Analogue Scale/Score (VAS) score and incidence of adverse reactions are observed in 2 groups. The correlation of sedation score with oxidative stress index and pain degree is analyzed. The experimental results show that Rimazolam has a good anesthesia induction effect in hip replacement, but the low dose (0.3 mg/kg) can reduce the level of oxidative stress in patients, has a better sedation effect and can maintain the stability of patients’ hemodynamic indicators, and has a positive effect on relieving postoperative pain in patients. [Clinical Trial Registration Number- ChiCTR2000038548].